The EU had previously approved two vaccines for protecting ... "This approval of the first mRNA vaccine against RSV clearly shows the importance of innovation when it comes to protecting the ...

GSK plc GSK has announced the approval of the European Commission (EC) for the expanded use of its respiratory syncytial ...

The company's vaccine consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein.

The EU follows the US in approving the use of the shot in the younger age range in people with conditions like chronic ...

Vaccination against respiratory syncytial virus for adults over 60 is likely to be cost-effective by preventing illness, ...

London open The FTSE 100 is expected to open 10 points higher on Thursday, having closed down 0.02% on Wednesday at 8,343.85.

In adults 60 and over, vaccine effectiveness from October 2023 to March 2024 against RSV-associated hospitalization reached ...

CORRECTION: An earlier version of this story misstated the number of RSV vaccines ... after the vaccine had been approved. “There were a lot of kinks last year to work out for the first time ...

The European Commission on Friday approved Moderna's respiratory syncytial virus (RSV) vaccine for older adults -- the first ...